<DOC>
	<DOCNO>NCT00894322</DOCNO>
	<brief_summary>This study design evaluate pharmacokinetics , tolerability , safety exenatide weekly suspension healthy subject subject type 2 diabetes . The study also evaluate efficacy type 2 diabetes patient . Development exenatide weekly presentation would eliminate need reconstitute product prior use .</brief_summary>
	<brief_title>A Study Examine Pharmacokinetics , Tolerability , Safety Efficacy Exenatide Once Weekly Suspension</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Cohort 1 : Is 19 65 year old Has body mass index ( BMI ) 23 kg/m2 35 kg/m2 , inclusive , study start Cohort 2 : Is 19 75 year old Has diagnose type 2 diabetes mellitus Has HbA1c 7.1 % 10.0 % , inclusive , study start Has body mass index ( BMI ) 25 kg/m2 45 kg/m2 , inclusive , study start Has treat diet exercise alone stable regimen metformin , TZD , combination metformin TZD , minimum 2 month prior study start Either treat stable treatment regimen follow medication minimum 2 month prior study start : Hormone replacement therapy ( female subject ) Oral contraceptive ( female subject ) Antihypertensive agent Lipidlowering agent Thyroid replacement therapy Antidepressant agent Cohort 1 : Has personal history diabetes mellitus ( include impair glucose tolerance , impair fast glucose , gestational diabetes ) Has receive investigational drug within 30 day ( 5 halflives investigational drug , whichever great ) prior study start Has ever expose exenatide ( BYETTA , exenatide weekly , formulation exenatide ) GLP 1 analog Cohort 2 : Has receive investigational drug within 30 day ( 5 halflives investigational drug , whichever great ) prior study start Has ever expose exenatide ( BYETTA , exenatide weekly , formulation exenatide ) GLP 1 analog Has treat , currently treat , expect require undergo treatment follow treatmentexcluded medication : Any DPP4 inhibitor sulfonylurea ( SU ) within 3 month prior study start Alpha glucosidase inhibitor , meglitinide , nateglinide , pramlintide ( SYMLIN® ) within 30 day prior study start Insulin within 2 week prior study start 1 week within 3 month prior study start Systemic corticosteroid oral , intravenous , intramuscular route ; potent , inhale , intrapulmonary ( include ADVAIR® ) steroid know high rate systemic absorption Prescription overthecounter weight loss medication within 3 month prior study start</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>diabetes</keyword>
	<keyword>exenatide weekly</keyword>
	<keyword>Byetta</keyword>
	<keyword>Amylin</keyword>
	<keyword>Lilly</keyword>
</DOC>